600645 Stock Overview
Primarily engages in the preparation and storage of cell detection tests in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 600645 from our risk checks.
Vcanbio Cell & Gene Engineering Corp., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥18.18 |
| 52 Week High | CN¥21.99 |
| 52 Week Low | CN¥12.88 |
| Beta | 0.27 |
| 11 Month Change | 5.39% |
| 3 Month Change | 8.34% |
| 1 Year Change | 3.77% |
| 33 Year Change | -17.25% |
| 5 Year Change | -3.30% |
| Change since IPO | -61.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600645 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 6.1% | -1.0% | -1.7% |
| 1Y | 3.8% | -25.3% | -20.6% |
Return vs Industry: 600645 exceeded the CN Biotechs industry which returned -25.3% over the past year.
Return vs Market: 600645 exceeded the CN Market which returned -20.6% over the past year.
Price Volatility
| 600645 volatility | |
|---|---|
| 600645 Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.6% |
| 10% least volatile stocks in CN Market | 3.6% |
Stable Share Price: 600645 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600645's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 2,209 | Hongqi Wang | www.vcanbio.com |
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell detection tests in the People’s Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug safety guidance, disease genetic testing, and disease susceptibility testing for children and adults; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products.
Vcanbio Cell & Gene Engineering Corp., Ltd Fundamentals Summary
| 600645 fundamental statistics | |
|---|---|
| Market cap | CN¥8.29b |
| Earnings (TTM) | CN¥108.96m |
| Revenue (TTM) | CN¥1.59b |
76.1x
P/E Ratio5.2x
P/S RatioIs 600645 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600645 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.59b |
| Cost of Revenue | CN¥499.84m |
| Gross Profit | CN¥1.09b |
| Other Expenses | CN¥985.13m |
| Earnings | CN¥108.96m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 68.64% |
| Net Profit Margin | 6.84% |
| Debt/Equity Ratio | 0.3% |
How did 600645 perform over the long term?
See historical performance and comparison